Trial: 202008068

A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase

III

Principal Investigator

Waqar, Saiama

Disease Site

Lung

Learn more about this study at: clinicaltrials.gov